Many patients never reach a trial because community settings often have less access to referrals than academic centers, where ...
Direct-to-consumer platforms for prescription medicines are growing, but patients need support to use them as part of a ...
This opportunity that HEDIS has created for patients who were too often discharged and forgotten is well past due — but it’s ...
Health systems are jumping to integrate AI into clinicians' everyday tools. When those platforms also offer the medical ...
Sickle cell disease and beta thalassemia are the startup’s lead indications. While gene therapies are available for both ...
Another panelist — Dr. Warris Bokhari, CEO of Claimable — agreed that it should be a qualified human making the decision on ...
Duet, a network of nurse practitioner-owned primary care practices, announced on Thursday that it raised $15 million in ...
Oyster Therapeutics’ lead program penetrates the brain to degrade pathological tau associated with Alzheimer’s disease. Eli ...
Patients increasingly expect convenient, consumer-focused healthcare experiences, panelists said at the recent MedCity INVEST ...
Bayer’s asundexian, brand name Sunharbo, is the first FDA-approved drug in a new class cardiovascular medicines Approval of ...
Sanofi’s Infilbray is now approved for treating Gaucher disease type 3. The brain-penetrating small molecule is the first FDA-approved therapy for the neurological symptoms of this rare enzyme ...
Blackstone Life Sciences is placing a bet on Pfizer’s berobenatide, a GLP-1 drug designed for monthly dosing. This GLP-1 drug comes from Metsera, which Pfizer acquired last year in a $10 billion deal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results